Evidence map›Paper›PMID 38921182›Full record

ArticleHematology reports2024

Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma.

Satoshi Yamasaki, Hiroatsu Iida, Akio Saito, Morio Matsumoto, Yoshiaki Kuroda, Tohru Izumi, Akiko M Saito, Hiroaki Miyoshi, Koichi Ohshima, Hirokazu Nagai and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Satoshi YamasakiDepartment of Internal Medicine, Kyushu University Beppu Hospital, 4546 Tsurumihara, Tsurumi, Beppu 874-0838, Japan.ORCID 0000-0002-6143-7906
Hiroatsu IidaDepartment of Hematology and Oncology Research, NHO Nagoya Medical Center, Nagoya 460-0001, Japan.
Akio SaitoDepartment of Hematology, NHO Shibukawa Medical Center, Shibukawa 377-0204, Japan.
Morio MatsumotoDepartment of Hematology, NHO Shibukawa Medical Center, Shibukawa 377-0204, Japan.
Yoshiaki KurodaDepartment of Hematology, NHO Hiroshimanishi Medical Center, Otake 739-0696, Japan.
Tohru IzumiDepartment of Hematology, NHO Sendai Medical Center, Sendai 983-8520, Japan.
Akiko M SaitoDepartment of Hematology and Oncology Research, NHO Nagoya Medical Center, Nagoya 460-0001, Japan.ORCID 0000-0003-3723-8445
Hiroaki MiyoshiDepartment of Pathology, School of Medicine, Kurume University, Kurume 830-0011, Japan.ORCID 0000-0002-2356-3725
Koichi OhshimaDepartment of Pathology, School of Medicine, Kurume University, Kurume 830-0011, Japan.
Hirokazu NagaiDepartment of Hematology and Oncology Research, NHO Nagoya Medical Center, Nagoya 460-0001, Japan.
Hiromi IwasakiDepartment of Hematology, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka 810-0065, Japan.

Funding

JSPS KAKENHI 22K12887
6 · The paper itself

Abstract

Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. The objective of this study was to characterize the safety and efficacy of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin (GDP) therapy (GDPR). This study of patients treated between March 2019 and March 2021 was registered with the Japan Registry of Clinical Trials (registration number: jRCT0000000519). If complete response, partial response, or stable disease was confirmed after 2-4 GDP cycles, romidepsin was administered every 4 weeks for 1 year. Seven patients with relapsed/refractory (R/R) PTCL (T-follicular helper phenotype [n = 1] and angioimmunoblastic T-cell lymphoma [n = 6]) were included in this prospective study (PTCL-GDPR). After a median follow-up of 34 months of patients in PTCL-GDPR, the 2-year overall survival rate was 71%, and the overall response rate after treatment was 57%. Common adverse events in patients with PTCL-GDPR included hematological toxicities such as neutropenia, which improved with supportive treatment. There were no treatment-related mortalities. GDPR might be safe and effective in elderly transplant-ineligible patients with R/R PTCL; however, further investigation is required.

Indexed as

angioimmunoblastic T-cell lymphomacisplatingemcitabineolderperipheral T-cell lymphoma not otherwise specifiedromidepsintransplant-ineligible

Identifiers

PMID38921182
PMCPMC11204088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.